Sativex <sup>®</sup> as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

2018141 citationsJournal Article

Authors

Jolana Marková · Thomayer University Hospital

Ute Essner

Bülent Akmaz · Almirall (Germany)

M. Marinelli · Almirall (Spain)

C. Trompke · Almirall (Germany)

Arnd Lentschat · Almirall (Germany)

Carlos Vila · Almirall (Spain)

Abstract

Add-on THC:CBD oromucosal spray provided better and clinically relevant improvement of resistant MS spasticity compared with adjusting first-line antispasticity medication alone.

Topics & Keywords

Toxin Mechanisms and Immunotoxins Multiple Sclerosis Research Studies Botulinum Toxin and Related Neurological Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: International Journal of Neuroscience

Volume 129, Issue 2, pp. 119-128

DOI: 10.1080/00207454.2018.1481066

Field-Weighted Citation Impact: 5.33